Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 9:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 607 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo three times a day (TID) Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Do NSAIDS or Executing Exercise Decrease Local Erythema, Site Swelling & Pain After INoculation

NCT02807623
View directory record Official record
Conditions
Immune System and Related Disorders
Interventions
Ibuprofen, Compound Exercise of Push-ups, oral placebo
Drug · Behavioral
Lead sponsor
Womack Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Bethesda, Maryland • Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 11, 2026, 9:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Green Vegetables and Women's Health

NCT01726127
View directory record Official record
Conditions
Dietary Modification
Interventions
Broccoli and Brussels Sprouts, Cruciferous Complete, Placebo
Other · Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years to 50 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 11, 2026, 9:47 AM EDT
Withdrawn Phase 2 Interventional

Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy

NCT00723918
View directory record Official record
Conditions
HIV-associated Neuropathy, Polyneuropathy
Interventions
SAB378, methadone, SAB placebo, Methadone placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
San Diego, California • Brooklyn, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 11, 2026, 9:47 AM EDT
Terminated Not applicable Interventional Results available

Effect of Fenugreek on Milk Production

NCT00851591
View directory record Official record
Conditions
Lactation
Interventions
fenugreek, Placebo (Psyllium)
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 11, 2026, 9:47 AM EDT
Completed Early Phase 1 Interventional

Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon

NCT02583789
View directory record Official record
Conditions
Raynaud's Phenomenon
Interventions
oral treprostinil, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 11, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

NCT02855450
View directory record Official record
Conditions
Glaucoma
Interventions
rhNGF, Vehicle
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 11, 2026, 9:47 AM EDT
Completed Phase 1Phase 2 Interventional

Automated Abdominal Binder for Orthostatic Hypotension

NCT03482297
View directory record Official record
Conditions
Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy
Interventions
automated abdominal binder, Sham binder, Placebo, Midodrine
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 11, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

Medication Development in Alcoholism: Acamprosate Versus Naltrexone

NCT00656630
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Naltrexone, Placebo
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 11, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease

NCT02976129
View directory record Official record
Conditions
Crohn's Disease
Interventions
V565, Placebo
Drug
Lead sponsor
VHsquared Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Anaheim, California • Clearwater, Florida • Miami Springs, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 11, 2026, 9:47 AM EDT
Recruiting Not applicable Interventional

Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting

NCT07126301
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Aromatherapy and Essential Oils, Questionnaire Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 11, 2026, 9:47 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Quetiapine Treatment for Pediatric Delirium

NCT03572257
View directory record Official record
Conditions
Delirium
Interventions
Quetiapine, Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 11, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury

NCT00597818
View directory record Official record
Conditions
NSAID-induced Gastroduodenal Injury, Ulcers, Rheumatoid Arthritis, Osteoarthritis
Interventions
Cobiprostone, Placebo, Non-steroidal anti-inflammatory drug
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
40 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Phoenix, Arizona • Chula Vista, California • Loma Linda, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 11, 2026, 9:47 AM EDT
Terminated Phase 2 Interventional Results available

Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy

NCT01168908
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Interventions
Sildenafil
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 11, 2026, 9:47 AM EDT
Withdrawn Early Phase 1 Interventional

A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment

NCT02878538
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Deferiprone, Placebo phase
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 11, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Blood Flow and Vascular Function in Cystic Fibrosis

NCT02057458
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sildenafil (Acute-1 hour), Sildenafil (Subchronic-4 weeks), Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 11, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

NCT00724126
View directory record Official record
Conditions
Non-Constipation Irritable Bowel Syndrome
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
88
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 11, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects

NCT01702649
View directory record Official record
Conditions
Healthy Volunteers, Bacterial Infections
Interventions
RPX2003 (Biapenem), Placebo
Drug
Lead sponsor
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 11, 2026, 9:47 AM EDT
Completed Not applicable Interventional Results available

5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence

NCT01549652
View directory record Official record
Conditions
Opioid Withdrawal, Physical Dependence
Interventions
Ondansetron, Placebo, Morphine, Naloxone 0.4 mg/70 kg, Naloxone 0.8 mg/70 kg
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 11, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction

NCT02918552
View directory record Official record
Conditions
Heart Failure
Interventions
sodium nitrite, Control
Drug
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
70 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 11, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

NCT02072824
View directory record Official record
Conditions
Partial Onset Seizures
Interventions
Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Month to 3 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Orlando, Florida • Tampa, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 11, 2026, 9:47 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effect of Nasaleze on Nasal Challenge With Allergen

NCT01723397
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Nasaleze Spray, Placebo spray, Allergen
Drug · Other · Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 11, 2026, 9:47 AM EDT
Suspended Phase 1Phase 2 Interventional

Propranolol Treatment for Postoperative Chylothorax

NCT06833320
View directory record Official record
Conditions
Postoperative Chylothorax, Congenital Heart Disease, Open Heart Surgery, Chylothorax
Interventions
Propranolol Hydrochloride, Placebo
Drug
Lead sponsor
June Wu
Other
Eligibility
7 Days to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 11, 2026, 9:47 AM EDT
Withdrawn Phase 4 Interventional

Treating Toddler Obesity by Treating the Parent/Caregiver Obesity With Weight Loss Medications

NCT06768320
View directory record Official record
Conditions
Weight Loss, Obesity, Childhood, Obesity
Interventions
Lomaira 8Mg Tablet
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
12 Months to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 11, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis

NCT00853242
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Placebo, Genz-644470, Sevelamer carbonate
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
52
States / cities
Alexander City, Alabama • Birmingham, Alabama • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 11, 2026, 9:47 AM EDT